T cell infusion therapy for an immune-checkpoint inhibitor-resistant tumor, said pharmaceutical composition containing an antigen-encapsulated nano gel, wherein the antigen-encapsulated nano gel comprises a long-chain peptide antigen or a protein antigen each of which is encapsulated in a hydrophob...
随着对病毒感染的易感性相应增加,这些感染中有相当一部分可以通过预防措施或适当的治疗干预得到有效纠正。 CAR-T细胞输注(CAR-T-cell infusion,CTI)前 在CTI前,感染风险增加与基础血液恶性肿瘤相互交织。多线治疗也是导致恶性肿瘤感染易感性...
et al. Genetic ablation of HLA class I, class II, and the T-cell receptor enables allogeneic T cells to be used for adoptive T-cell therapy. Cancer Immunol. Res. 8, 926–936 (2020). CAS PubMed Google Scholar Cruz, C. R. et al. Infusion of donor-derived CD19-redirected virus-...
CAR-T细胞疗法（Chimeric Antigen Receptor T-Cell Therapy）是一种创新的细胞治疗方法，通过基因工程技术改造患者自身的T细胞，使其具备识别和杀伤特定癌细胞或病变细胞的能力。这种疗法在治疗某些类型的血液癌症（如白血病和淋巴瘤）中取得了显著效果。治疗过程：采集T细胞： 从患者的血液中提取T细胞，通常通过血液分离技术...
” After the infusion of CAR T cells, the cancer cells in the patient will theoretically be eliminated in a certain time, Prof. Hu Yu introduced. That said, the CAR T-cell therapy works well against hematological malignancies, including lymphoma, leukemia and multiple myeloma, but its ...
or excision. He had developed metastases in the groin lymph nodes and in 1 lung. Two months after the T cell infusion, the tumors were no longer visible on positron emission tomography (PET) or computed tomography (CT) scans. He was still disease-free 2 years later, at his most recent...
在嵌合抗原受体-传统T细胞(chimeric antigen receptor-conventional T cell therapy,CAR-Tconv)的应用中,抗原非依赖性信号转导会导致进行性的 CAR-T 失活与耗竭,从而限制 CAR-T 的功能;在 CAR-Treg 中,4-1BB 共刺激结构域(co-...
Chimeric antigen receptor-T cell therapy, a groundbreaking cancer treatment, has achieved remarkable success against hematologic malignancies. However, CAR-T monotherapy faces challenges in certain cases, including treatment tolerance and relapse rates.
A. et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333, 1038–1044 (1995).A human trial that shows that infusion of in vitro -expanded CMV-specific T-cell lines is ...
Significant advances have been made in chimeric antigen receptor T (CAR-T)-cell therapy for the treatment of recurrent or refractory B-cell hematologic malignancies. However, CAR-T-cell therapy has not yet achieved comparable success in the management of